Submitted by Anonymous (not verified) on 19 September 2024 - 13:28
Opinion/decision on a Paediatric investigation plan (PIP): Kisplyx, Lenvatinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0528/2022
Source: